CH Biotech R&D Co., Ltd. (6534.TW) develops and manufactures active pharmaceutical ingredients (APIs), key starting materials (KSMs), and advanced intermediates primarily for the anti-diabetic and cardiovascular drug markets; its core offerings include generic APIs such as Sitagliptin, Vildagliptin, Linagliptin, Dapagliflozin, and Empagliflozin under strict cGMP compliance, alongside custom synthesis services and biocatalysis technologies leveraging enzymatic processes for chiral compounds. The company operates production facilities in Taiwan and serves global pharmaceutical clients in North America, Europe, and Asia, with headquarters in Taoyuan City, Taiwan, where it was founded in 2006. In recent developments, CH Biotech expanded its manufacturing capacity through a new biocatalysis plant commissioned in 2024 to meet rising demand for green chemistry solutions; it formed a strategic partnership with a major European pharma firm in mid-2025 for co-development of novel GLP-1 receptor agonist intermediates and secured a NT$500 million funding round in late 2024 to support R&D in oligonucleotide APIs. These initiatives mark a shift toward high-value biologics and sustainable production, complementing its established small-molecule portfolio.